新产品介绍[ADV-7103(新组合),菊Erwinia,恩格列净(新适应症),MVC-COV-1901, ON-101,彭普利单抗,ponesimod, sotorasib, upacicalcet sodium hydrate, upadacitinib酒石酸盐(新适应症),zimberelimab, ZyCoV-D]

{"title":"新产品介绍[ADV-7103(新组合),菊Erwinia,恩格列净(新适应症),MVC-COV-1901, ON-101,彭普利单抗,ponesimod, sotorasib, upacicalcet sodium hydrate, upadacitinib酒石酸盐(新适应症),zimberelimab, ZyCoV-D]","authors":"","doi":"10.1358/dot.2021.57.11.3381582","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":85144,"journal":{"name":"Medicamentos de actualidad. Drugs of today","volume":"50 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New product intros [ADV-7103 (new combination), asparaginase Erwinia chrysanthemi, empagliflozin (new indication), MVC-COV-1901, ON-101, penpulimab, ponesimod, sotorasib, upacicalcet sodium hydrate, upadacitinib tartrate (new indication), zimberelimab, ZyCoV-D]\",\"authors\":\"\",\"doi\":\"10.1358/dot.2021.57.11.3381582\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":85144,\"journal\":{\"name\":\"Medicamentos de actualidad. Drugs of today\",\"volume\":\"50 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicamentos de actualidad. Drugs of today\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1358/dot.2021.57.11.3381582\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicamentos de actualidad. Drugs of today","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1358/dot.2021.57.11.3381582","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
New product intros [ADV-7103 (new combination), asparaginase Erwinia chrysanthemi, empagliflozin (new indication), MVC-COV-1901, ON-101, penpulimab, ponesimod, sotorasib, upacicalcet sodium hydrate, upadacitinib tartrate (new indication), zimberelimab, ZyCoV-D]
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
New product intros [ezetimibe/pitavastatin (new combination), ozoralizumab, ripasudil/brimonidine (new combination), spesolimab, valemetostat tosylate (first-in-class), valoctocogene roxaparvovec] Asparaginase Erwinia chrysanthemi for acute lymphoblastic leukemia and lymphoblastic lymphoma. Bimekizumab for psoriasis. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1